ArticleFrontiers in reproductive health2026
Basal androgen status as a modifiable predictor of poor ovarian response in controlled ovarian hyperstimulation.
Article in Frontiers in reproductive health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ovarian response to controlled ovarian hyperstimulation (COH) is commonly predicted by age, ovarian reserve markers, and outcomes of previous stimulation cycles. Androgens play a key role in follicular recruitment, development, and atresia. This study aimed to evaluate circulating androgens as additional, potentially modifiable prognostic markers of ovarian response. Materials and methods: We conducted a retrospective cohort study analyzing oocyte yield after COH in relation to early follicular phase androgen levels. Expected ovarian response was classified according to the Bologna criteria. Odds ratios (ORs) for androgen levels and oocyte yield were calculated, and receiver operating characteristic (ROC) curves were generated to assess the predictive accuracy of androgen levels for normal versus poor ovarian response (NOR/POR). Results: A total of 299 stimulation cycles were analyzed (216 NOR and 83 POR). The POR group was characterized by significantly higher median age, lower anti-Müllerian hormone (AMH) levels, reduced oocyte yield, and significantly lower androgen concentrations. A significant positive correlation was observed between the number of retrieved oocytes and both AMH and testosterone levels. The odds of retrieving more than three oocytes were increased for testosterone levels >0.21 ng/mL (OR: 2.67) and for DHEAS levels >0.93 ng/mL (OR: 1.37). While AMH demonstrated the strongest predictive performance for an unfavorable outcome (oocyte yield ≤3; AUC: 0.877), androgen levels showed a moderate predictive ability for poor ovarian response (testosterone AUC: 0.659; DHEAS AUC: 0.610). Discussion: Considering the observed association between androgen levels and ovarian response, the assessment of androgens prior to COH may provide additional prognostic value. Androgens could represent modifiable biomarkers to identify patients who may benefit from pre-treatment androgen supplementation in the presence of low baseline levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.